Lv31
260 积分 2023-07-05 加入
Phase Ib study of anlotinib in combination with anti‐PD‐L1 antibody (TQB2450) in patients with advanced acral melanoma
6小时前
已完结
Statistical Considerations for the Next Generation of Clinical Trials
7个月前
已完结
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
7个月前
已完结
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
8个月前
已完结
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
9个月前
已完结
Prognostic Factors in High-Grade Osteosarcoma of theExtremities or Trunk: An Analysis of 1,702 Patients Treatedon Neoadjuvant Cooperative Osteosarcoma Study GroupProtocols
9个月前
已完结
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
9个月前
已完结
The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity
9个月前
已完结
Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy
10个月前
已完结
In vitro studies of H520 cell cycle and apoptosis by anlotinib combined with radiotherapy
10个月前
已完结
皖公网安备34019202002308
